FredTownsendValentineMD

Grant Support

• AdministrativeNational Institute Of Allergy And Infectious Diseases2010
• Center For AIDS ResearchNational Institute Of Allergy And Infectious Diseases2000–2010
• Immunopathogenesis Of Acute And Early HIV InfectionNational Institute Of Allergy And Infectious Diseases2004–2009
• CD4 Responses To Antiretroviral Therapy (ART) Alone Or ART With VaccinationNational Center For Research Resources2006–2008
• Immunological Control Of HIV In VivoNational Institute Of Allergy And Infectious Diseases2004–2008
• Immune Responses To Acute HIV InfectionNational Institute Of Allergy And Infectious Diseases2004–2008
• OAR SupplementNational Institute Of Allergy And Infectious Diseases2005
• Administrative CoreNational Institute Of Allergy And Infectious Diseases2005
• ACTG A5150: Virologic &Immunologic Changes In Women With HIV During PostpartumNational Center For Research Resources2005
• ACTG A5116: Protease Inhibitor Sparing Regimens V Nucleoside-Sparing RegimensNational Center For Research Resources2005
• ACTG A5082: Metformin &Rosiglitazone In HIV+ PTS W/ Insulin &Fat AbnormalitiesNational Center For Research Resources2004–2005
• ACTG 5084: Metabolic Complications In Hiv-1-Infected Pregnant Women On ARTNational Center For Research Resources2004–2005
• HIV Pathogenesis And Responoses To Therapy In AfricansNational Institute Of Allergy And Infectious Diseases2004
• Temporary Cessation Of Antiretroviral Treatment In Patients Failing TherapyNational Center For Research Resources2004
• Predictive Value Of Pk-Adjusted Phenotypic Susceptibility On Antiretroviral RESPNational Center For Research Resources2004
• Effect Of Thymidine Analogue Change To Nucleoside-Sparing Regimen On Fat WastingNational Center For Research Resources2004
• Augmentation Of Immune Response Through Vaccination In Individuals On HaartNational Center For Research Resources2004
• Adult AIDS Clinical Trial Group Longitudinal Linked Randomized Trials ProtocolNational Center For Research Resources2004
• ACTG A5173:Clearance Of HIV-1 In CD4+ Cells Of Subjects On T-20 PLUS Oral ARNational Center For Research Resources2004
• ACTG A5172: Using Helper And CTL Responses To Control VNational Center For Research Resources2004
• ACTG A5164:Immediate VS Delayed ART For Hiv-Infected Patients With Acute OTNational Center For Research Resources2004
• ACTG A5163: Alendronate In HIV Subjects With DecreasedNational Center For Research Resources2004
• ACTG A5150: Virologic &Immunologic Changes In Women WINational Center For Research Resources2004
• ACTG A5146: Therapeutic Drug Monitoring In Subjects With A Low Niq To PisNational Center For Research Resources2004
• ACTG A5143: Lopinavir (Lpv)/Ritonavir (RTV) VS Gw433908/Rtv VS Lpv/Rtv/Gw433908National Center For Research Resources2004
• ACTG A5135: Fixed- VS Adjusted-Dose Lopinavir/RitonavirNational Center For Research Resources2004
• ACTG A5128: Obtaining Informed Consent To Use Stored Human Biological MaterialsNational Center For Research Resources2004
• ACTG A5127: Treatment Of Lamivudine-Resistant HBV/HIV Co-Infected SubjectsNational Center For Research Resources2004
• ACTG A5116: Protease Inhibitor Sparing Regimens V. Nucleoside-Sparing RegimensNational Center For Research Resources2004
• ACTG A5115: Antiretroviral Switch At Lower Versus Higher HIV-1 RNA LevelsNational Center For Research Resources2004
• ACTG A5103:Protease Inhibitor-Sparing Regimens To Improve Metabolic AbnormalitieNational Center For Research Resources2004
• ACTG A5095: 3 Protease Inhibitor-Sparing Regimens For Initial Treatment Of HIVNational Center For Research Resources2004
• ACTG A5092s: Pharmacokinetic Effects Of Rbv On ZDV Or D4T Triphosphate FormationNational Center For Research Resources2004
• ACTG A5079: Testosterone Supplementation For Hiv-Positive MenNational Center For Research Resources2004
• ACTG A5073:Twice Daily -V- Once Daily Haartand Self-Administered Versus DOTNational Center For Research Resources2004
• ACTG A5068: Withdrawal Of Antiretrovirals + HIV VaccineNational Center For Research Resources2004
• ACTG A5030: Valganciclovir For Pre-Emptive Therapy For CytomegalovirusNational Center For Research Resources2004
• ACTG A5029: Human Papilloma Virus In Antiretroviral Naive HIV+ Women On HaartNational Center For Research Resources2004
• ACTG 736: CSF HIV-1 &Cognitive Function In Patients On Potent HaartNational Center For Research Resources2004
• ACTG 372: Indinavir + Nucleoside Analogs: Virologic Success And FailureNational Center For Research Resources2004
• ACTG 371: 3tc/Zdv/Abc/Apv In Acute HIV Infection Or SeroconversionNational Center For Research Resources2004
• ACTG A5170: Predictors Of Disease Progression In Subjects WHO Discontinue ARTNational Center For Research Resources2004
• ACTG A5142: Comparison Of Three Antiviral Regimens For Initial Therapy Of HIV-1National Center For Research Resources2004
• ACTG 362: Azithromycin Prophylaxis For Primary Prevention Of MAC In AIDSNational Center For Research Resources1999–2004
• Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1996–2003
• TRI 003: T 20 Administered To HIV+ Adults By SQ Infusion V SQ InjectionNational Center For Research Resources1999–2002
• ACTG 398: Amprenavir + Abacavir, Efavirenz &Adefovir In HIV+ PTSNational Center For Research Resources1999–2002
• ACTG 388: Efz + Nfv W/ 3tc/Zdv &Idv In HIV+ PTS W/ CD4 <200 &>100,National Center For Research Resources1999–2002
• ACTG 384: PI +/ Nnrti W/ Dual Nucleosides For Initial RX Of HIV InfectionNational Center For Research Resources1999–2002
• ACTG 365:Steady State Pharmacokinetic Interaction Study Of IndinavirNational Center For Research Resources1999–2002
• ACTG 363: Cidofovir For Progressive Multifocal Leukoencephalopathy In AIDSNational Center For Research Resources1999–2002
• ACTG 334:Cyclosporin In Immune Activation &Hiv Expression In Early HIVNational Center For Research Resources1999–2002
• Zdv/3tc/Nevirapine And Zdv/3tc/Nevirapine/1592u89 In Hiv-Infected ChildrenNational Center For Research Resources1998–2002
• Three Regimens For Hiv-Infected Subjects On Zdv, Lamivuidine And IndinavirNational Center For Research Resources1998–2002
• Rhil2 In HIV+ Subjects On Haart Compared To Haart AloneNational Center For Research Resources1998–2002
• Oral Isotretinoin Versus Observation For Low Grade Cervical DysplasiaNational Center For Research Resources1998–2002
• Nelfinavir AND/OR Dmp-266 PLUS Nucleoside Analogs In Nucleoside ExperienceNational Center For Research Resources1998–2002
• Indinavir, Dmp-266 And 1592U89 In Hiv-Infected SubjectsNational Center For Research Resources1998–2002
• Indinavir PLUS Nucleoside Analogs--Virologic Success And FailureNational Center For Research Resources1998–2002
• Fluconazole In HIV+ Subjects With Recurrent Oropharyngea CandidiasisNational Center For Research Resources1998–2002
• Activity Of Soft Gel Capsule Of Saquinavir In Antiretroviral RegimensNational Center For Research Resources1998–2002
• 141w94/Vx-478+3tc+Zdv Or Nevirapine+3tc+StavudineNational Center For Research Resources1998–2002
• 141w94/Vx-478 PLUS ZDV PLUS 3TC In Hiv-Infected IndividualsNational Center For Research Resources1998–2002
• ACTG 320--Indinavir W/ ZDV Or D4T &3tc In PTS W/ Cd4<200 &>3 Mon Prior ZDVNational Center For Research Resources1997–2002
• ACTG 307--Hydroxyurea +/- DDI Compared With DDI Alone In HIV Infected PatientsNational Center For Research Resources1997–2002
• Lymphokines On Metastatic Malignant MelanomaNational Center For Research Resources1996–2002
• IL-2 PLUS Antiretroviral Therapy Versus Antiretroviral Alone In HIV+ PatientsNational Center For Research Resources1996–2002
• Core--Flow Cytometry FacilityNational Institute Of Allergy And Infectious Diseases2001
• Cryptic Epitopes--Immunization By Multiple Chain PeptideNational Institute Of Allergy And Infectious Diseases1998–2001
• Rhil 12 For CD4 LESS THAN 50 And Between 300-500National Center For Research Resources2000
• Lamivudine, Zidovudine, Abacavir, PLUS Amprenavir In HIVNational Center For Research Resources2000
• HIV RNA Suppression With Ddi/4td/Hu VS Ddi/D4t/EfvNational Center For Research Resources2000
• Hepatitis C Dynamics With HIV And AIDS TherapyNational Center For Research Resources2000
• Discontinuing Therapy In Disseminated Mycobacterium AviuNational Center For Research Resources2000
• Discontinuing PCP Prophylaxis In AIDS Therapy--Cd4>200National Center For Research Resources2000
• Rhil-12 For HIV-1 Infected Subjects With Cd4<50 And CD4 Between 300-500National Center For Research Resources1998–1999
• Remune/Triple Antiviral Drugs On HIV-1 Specific Immunogenicity When Cd>400National Center For Research Resources1998–1999
• Core--DevelopmentalNational Institute Of Allergy And Infectious Diseases1997–1999
• AIDS ResearchNational Institute Of Allergy And Infectious Diseases1997–1999
• ACTG 333--Antiviral Effect Of Switching Formulations Of Saquinivir VS IndinvirNational Center For Research Resources1997–1999
• ACTG 303--Influence Of Risk Status On Response To Antiretroviral InterventionsNational Center For Research Resources1997–1999
• ACTG 302--Virologic Responses To New Nucleoside Regimens After Prolonged Zdv/DdiNational Center For Research Resources1997–1999
• ACTG 277--Dapsone Versus Atovaquone For PCP Prophylaxis In HIV Infected PatientsNational Center For Research Resources1997–1999
• ACTG 244--Zidovudine Alone Or In Combination With Other Antivirals For HIVNational Center For Research Resources1997–1999
• ACTG 183--Oral Ganciclovir For Cytomegalovirus Gastrointestinal Disease In AIDSNational Center For Research Resources1997–1999
• Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
• Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
• Outreach AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
• Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
• Neurology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
• Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
• HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
• Core--Flow CytometryNational Institute Of Allergy And Infectious Diseases1996–1999
• Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases1996–1999
• Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
• Comparison Of 3 Recombinant HIV Envelope Vaccines In HIV Infected PatientsNational Center For Research Resources1996–1999
• Amphotericin B Oral Suspension For Fluconazole Resistant Oral CandidiasisNational Center For Research Resources1997
• ACTG 223--Clarithromycin In AIDS Patients With Mycobacterium Avium ComplexNational Center For Research Resources1997
• ACTG 222--Treatment Of Pulmonary Mycobacterium Tuberculosis And HIV InfectionNational Center For Research Resources1997
• ACTG 214--Comparative Trial Of Several HIV 1 Derived ImmunogensNational Center For Research Resources1997
• ACTG 177--Prophlaxis Against Mycobacterium Tuberculosis In HIV Positive PatientsNational Center For Research Resources1997
• Infectious Diseases And Basic Microbiological MechanismsNational Institute Of Allergy And Infectious Diseases1996–1997
• Single Versus Combination Therapy To Prevent Mycobacterium Avium ComplexNational Center For Research Resources1996–1997
• Nucleoside Therapy For Advanced HIV Disease With A CD4 Count <50 MM3National Center For Research Resources1996–1997
• Differences Among Various Zdv/Ddi Regimens Of Quantitative Measures Of HIVNational Center For Research Resources1996–1997
• Delavridine Mesylate PLUS ZDV AND/OR DDI VS ZDV PLUS DDI Combination TherapyNational Center For Research Resources1996–1997
• Viral And Cellular Gene Expression And Growth RegulationNational Cancer Institute1996–1997
• Trimethoprim/Sulfamethoxazole As Primary PCP ProphylaxisNational Center For Research Resources1996
• Influence Of Risk Status On Response To Antiretroviral InterventionsNational Center For Research Resources1996
• Immunologic And Virologic Responses To Combination Anti-Hiv TherapyNational Center For Research Resources1996
• Dapsone Versus Atovaquone For PCP Prophylaxis In HIV Infected PatientsNational Center For Research Resources1996
• Clarithromycin In AIDS Patients With Mycobacterium Avium ComplexNational Center For Research Resources1996
• Atovaquone PLUS Sulfadiazine Or Pyrimethamine For Toxoplasmic EncephalitisNational Center For Research Resources1996
• Amphotericin B Oral Suspension For Fluconazole Resistant Oral Candidiasis In HIVNational Center For Research Resources1996
• Zidovudine Alone Or In Combination With Other Antivirals For HIVNational Center For Research Resources1995–1996
• Treatment Of Pulmonary Mycobacterium Tuberculosis And HIV InfectionNational Center For Research Resources1995–1996
• Thalidomide For The Treatment Of Oral And Esophogeal Aphthous Ulcers In HIVNational Center For Research Resources1995–1996
• Single Versus Combination Therapy To Prevent Mycobacterium Avium ComplexNational Center For Research Resources1995–1996
• Delayed Type Hypersensitivity (DTH) Reactions To HIV Envelope AntigenNational Center For Research Resources1995–1996
• Alpha Interferon And Nucleoside Analogue Therapy For Hepatitis C In HIVNational Center For Research Resources1995–1996
• Active Immunization Of Asymptomatic HIV+ Patients With Recombinant GP160National Center For Research Resources1995–1996
• R0 31-8959 + ZDV VS ZDV + Zalcitabine VS R0 31-8959 + ZDV + ZalcitabineNational Center For Research Resources1994–1996
• Nucleoside Therapy For Advanced HIV Disease With A CD4 Count <50 MM3National Center For Research Resources1994–1996
• Comparison Of 3 Recombinant HIV Envelope Vaccines In HIV Infected PatientsNational Center For Research Resources1994–1996
• Comparative Trial Of Several HIV 1 Derived ImmunogensNational Center For Research Resources1994–1996
• Prophlaxis Against Mycobacterium Tuberculosis In HIV Positive PatientsNational Center For Research Resources1993–1996
• Core--Flow CytometryNational Institute Of Allergy And Infectious Diseases1989–1996
• Study Evaluating Penicillin G And Ceftriaxone Therapies For NeurosyphilisNational Center For Research Resources1995
• Atovaquone PLUS Sulfadiazine Or Pyrimethamine For Toxoplasmic EcephalitisNational Center For Research Resources1995
• AIDS Clinical TrialsNational Institute Of Allergy And Infectious Diseases1994–1995
• Safety And Efficacy Of Zidovudine For Asymptomatic HIV IndividualsNational Center For Research Resources1993–1995
• Developmental Immunology ResearchNational Institute Of Allergy And Infectious Diseases1992–1995
• Adult AIDS Clinical ResearchNational Institute Of Allergy And Infectious Diseases1992–1995
• Viral And Cellular Gene Expression And Growth RegulationNational Cancer Institute1988–1995
• Single VS Combination Therapy To Prevent Mycobacterium Avium ComplexNational Center For Research Resources1994
• An Efficacy And Safety Study Of 2'3'Ddi In AIDS Patients With Advanced ARCNational Center For Research Resources1994
• Active Immunization Of HIV Positive PTS With Recombinant GP160 HIV-1 AntigenNational Center For Research Resources1994
• Infectious Diseases &Basic Microbiological MechanismsNational Institute Of Allergy And Infectious Diseases1993–1994
• Phase I Dose Escalation Study Of Intravenous Hypericin For HIV InfectionNational Center For Research Resources1993–1994
• Penicillin G /Iv Ceftriaxone Therapy For Neurosyphilis In HIV Positive PatientsNational Center For Research Resources1993–1994
• Dideoxycytidine For HIV Positive Patients On Prior Zidovudine TherapyNational Center For Research Resources1993–1994
• Acyclovir Resistant Mucocutaneous Herpes Simplex Disease In AIDSNational Center For Research Resources1993–1994
• Pathogenicity Of HIV Isolates--Role In Fetal TransmissonNational Institute Of Allergy And Infectious Diseases1992–1994
• Safety, Efficacy, And Toxicity Of Zidovudine In Early Aids-Related ComplexNational Center For Research Resources1993
• Phase I-- Efficacy Of 2',3'Dideoxyinosine For Treatment Of Aids/ArcNational Center For Research Resources1993
• Multiple Drug Treatment Of Mycobacterium Avium In HIV Positive PatientsNational Center For Research Resources1993
• Efficacy Of Dideoxyinosine For AIDS Or ARC Patients Intolerant To ZidovudineNational Center For Research Resources1993
• Comparison Of Dideoxyinosine (DDI) And Zidovudine For Patients With AIDS Or ARCNational Center For Research Resources1993
• Active Immunization Of HIV Positive Patients With Recombinant GP160 HIV-1 AntigenNational Center For Research Resources1993
• Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1992–1993
• Primary Prophylaxis Of Cerebral Toxoplasmosis In HIV Positive PatientsNational Center For Research Resources1992–1993
• Oral Azithromycin And Pyrimethamine For Toxoplasmic Encephalitis In AIDSNational Center For Research Resources1992–1993
• Pathogenicity Of HIV Isolates: Role In Fetal TransmissonNational Institute Of Allergy And Infectious Diseases1991–1993
• DDI And Zvd Therapy For AIDS Or ARC Patients On Long-Term Zvd TreatmentNational Center For Research Resources1991–1993
• Correlates Or Markers Of Immunity In AIDSNational Institute Of Allergy And Infectious Diseases1987–1993
• Infectious Diseases And Basic Microbiological MechanismsNational Institute Of Allergy And Infectious Diseases1992
• Synthetic Hypericin For HIV Infected Patients With LESS THAN 300 CD4 LymphocytesNational Center For Research Resources1992
• Multiple Drug Regimens For Treatment Of M Avium In HIV Positive PatientsNational Center For Research Resources1992
• Intradermal GP160 For HIV Patients With MORE THAN 400 CD4 CellsNational Center For Research Resources1992
• Dideoxycytidine For HIV Positive Patients On Prior Zvd TherapyNational Center For Research Resources1992
• Correlates Of Markers Of Immunity In AIDSNational Center For Research Resources1992
• Comparison Of DDI And Zidovudine For Patients With AIDS Or ARCNational Center For Research Resources1992
• AZT Treatment For Hiv-Positive Asymptomatic PatientsNational Center For Research Resources1991–1992
• Active Immunization With Recombinant GP160 HIV-1 AntigenNational Center For Research Resources1991–1992
• 2',3'Dideoxyinosine For Treatment Of Aids/ArcNational Center For Research Resources1991–1992
• Fluconazole VS Amphotericin B In Treatment Of Cryptococcal Meningitis In AIDSNational Center For Research Resources1990–1992
• Efficacy Of DDI For AIDS Or ARC Patients Intolerant To ZDVNational Center For Research Resources1990–1992
• Bactrim VS Fansidar VS Pentamidine Aerosol For PCP In AIDSNational Center For Research Resources1989–1992
• AZT Therapy For Patients With Early Aids-Related ComplexNational Center For Research Resources1988–1992
• Zidovudine And Recombinant Alpha-2a Interferon For Kaposi'S Sarcoma In AIDSNational Center For Research Resources1991
• Intravenous Spiramycin In AIDS Patients With Cryptosporidial DiarrheaNational Center For Research Resources1991
• Immediate VS Delayed Foscarnet Therapy For CMV Retinitis In AIDS PatientsNational Center For Research Resources1991
• Foscarnet Salvage For Immediately Sight-Threatening CMV RetinitisNational Center For Research Resources1991
• Intravenous Ganciclovir Therapy For Peripheral CMV Retinitis In AIDSNational Center For Research Resources1990–1991
• Comparison Of 2', 3'(Ddi) And Zidovudine For Patients With AIDS Or ARCNational Center For Research Resources1990–1991
• Combination Of AZT And DHPG For Patients With AIDS And Cytomegalovirus InfectionNational Center For Research Resources1990–1991
• AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1989–1991
• Phase I Trial Of Ribavirin For AIDS And Advanced ARCNational Center For Research Resources1989–1991
• GM-CSF For Aids-Associated Large Cell Immunoblastin, Sn-Cleaved LymphomaNational Center For Research Resources1990
• Phase II Study Of 2',3'Dideoxyinosine For Treatment Of Aids/ArcNational Center For Research Resources1989–1990
• AZT For Hiv-Positive Asymptomatic PatientsNational Center For Research Resources1988–1990
• Biosynthesis In Normal And Virus Transformed CellsNational Cancer Institute1986–1990
• Intravenous IL-2 In The Propagation Of Tumor Infiltrating LymphokinesNational Center For Research Resources1989
• Combination Of AZT And DHPG For Patients With AIDS And CytomegalovirusNational Center For Research Resources1989
• AIDS Cryptococcal Meningitis--Fluconazile VS Amphotericin B TherapyNational Center For Research Resources1989
• HTLV-III Infection In Non-Drug Abusing Promiscuous FemalesNational Center For Research Resources1988–1989
• AZT In Patients With AIDS DementiaNational Center For Research Resources1988–1989
• AIDS Clinical Trials Unit (Conversion From Ateu)National Institute Of Allergy And Infectious Diseases1988
• Phase I Trial Of Ribavirin For AIDS And Advanced ARC, Ateu34National Center For Research Resources1988
• Phase I Of Combination Of AZT And DHPG For Patients With AIDS And CytomegalovirusNational Center For Research Resources1988
• Intravenous Interleukin-2 In The Propagation Of Tumor Infiltrating LymphokinesNational Center For Research Resources1988
• Efficacy And Toxicity Of Doxorubicin Treatment In Kaposi SarcomaNational Center For Research Resources1988
• Bactrim VS Fansidar VS Pentamidine Aerosol For PCP In AIDS, Ateu21National Center For Research Resources1988
• AIDS Cryptococcal Meningitis--Fluconazile VS Amphotericin B, Ateu26National Center For Research Resources1988
• Establishment Of AIDS Treatment Evaluation UnitsNational Institute Of Allergy And Infectious Diseases1986–1988
• HTLV-III Infection In Non-Drug Abusing Promiscuous FemaleNational Center For Research Resources1987
• Viral And Cellular Gene Expression And Growth RegulationNational Cancer Institute1986–1987
• Molecular Biology Of Aids-Related TumorsNational Cancer Institute1985–1986
• Biosynthesis In Normal And Virus-Transformed CellsNational Cancer Institute1985–1986
• Etiology And Immunological Basis Of The AID SyndromeNational Cancer Institute1985
• Cellular And Viral Control Of Oncogenic TransformationNational Cancer Institute1985
• Cell-Mediated Immunity In Humans: Mechanisms And UsesNational Cancer Institute1985